Exelixis, Inc.

Rule Changes

As of September 2026: Seeking FDA approval for zanzalintinib in metastatic colorectal cancer

Exelixis learned on September 10 that the FDA would delay its decision on zanzalintinib, its experimental colorectal cancer drug, by three months. The new deadline is March 3, 2027, after the agency deemed updated safety and efficacy data a major amendment to the application.

Updated Sep 11

Money Moves

As of September 2026: Originator of Cabometyx; fought OMCAZIO approval

The FDA cleared a Taiwanese drugmaker to sell an alternate-salt version of the $2.1 billion cancer drug cabozantinib in the United States. The final approval lands three days after a federal appeals court kept generic entry shut by upholding patents on the originator's salt form.

Updated Sep 11